We submit herewith unaudited financial Results for the quarter ended September 30, 2025, Statement of Assets and Liabilities, Cash Flow Statement and limited Review Report for the quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Raaj Medisafe India reported revenue of Rs 1,840.41 lakhs for Q2 FY26, up 68.8% YoY from Rs 1,090.57 lakhs. Half-yearly revenue grew 46.1% YoY to Rs 3,423.10 lakhs. Net profit for the quarter surged 77.3% YoY to Rs 172.66 lakhs, while H1 net profit nearly doubled to Rs 318.72 lakhs versus Rs 162.58 lakhs a year ago. EPS for the quarter rose to Rs 1.32 (from Rs 0.74) and Rs 2.44 for H1. The limited review report issued by statutory auditor GDK & Associates was clean with no qualifications. However, total borrowings stood at Rs 5,216 lakhs against equity of Rs 2,911 lakhs, pushing the debt-to-equity ratio to about 1.79x.
Strong top-line and bottom-line growth signals improving business momentum and could be positive for the stock. However, the sharp rise in borrowings and elevated leverage of ~1.79x is a red flag on the balance sheet that investors should monitor closely.